Anthera Pharmaceuticals Inc (Nasdaq:ANTH)
June 11th, 2018
With markets going up Anthera Pharmaceuticals Inc closed Tuesday up 18.90%, a $0.05 increase to close on $0.29. Two technical ‘scores’ for companies to be wary of are the Altman Z1 and the Piotroski2 scores. ANTH scored quite low for both, which could be indicators of trouble down the road (the Altman Z-Score is -82.89, and the Piotroski Score is 2). In addition to finishing higher, trading volumes were solid at 282% of normal which can indicate investors see opportunities.
ANTH outperformed the rest of the Healthcare sector which went up 0.10% today.
Anthera Pharmaceuticals Inc Info
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.
All amounts in USD unless otherwise indicated
(1) The Altman Z-Score calculation was first published in 1968 by Edward I. Altman, and is used for predicting the probability that a firm will go into bankruptcy within two years. An Altman Z-Score below 1.8 (Remember that Anthera Pharmaceuticals Inc’s score is -82.89) is the trigger to be alert for this situation. Some analysts believe this score is less relevant for some companies, in particular companies operating to accumulate users that may run at huge losses to scale up.
(2) The Piotrosky score is used to determine the best value stocks with nine being the best and zero being the worst. It is based on specific aspects of the company’s financial statements, such as positive net income, operating cash flow and asset turnover ratio. A score 0 0 is the worst (Anthera Pharmaceuticals Inc’s score is ), and 9 is the best.
Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US News Tribune. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.